Valeo Financial Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD

Key Points

• Valeo Financial Advisors LLC increased its stake in Gilead Sciences, Inc. by 26.7%, owning 13,262 shares valued at $1,470,000 as per the recent SEC filing.
• Several brokerages have raised their ratings on Gilead, with a consensus rating of "Moderate Buy" and an average target price of $117.17.
• Gilead Sciences declared a quarterly dividend of $0.79 per share, reflecting an annualized dividend yield of 2.7% and a payout ratio of 62.95%.

Valeo Financial Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,262 shares of the biopharmaceutical company's stock after buying an additional 2,795 shares during the period. Valeo Financial Advisors LLC's holdings in Gilead Sciences were worth $1,470,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in GILD. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences during the first quarter valued at about $25,000. Activest Wealth Management lifted its position in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the first quarter valued at approximately $29,000. Colonial Trust Advisors lifted its position in Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its holdings in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GILD. Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a report on Saturday, September 27th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Finally, Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a report on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $117.17.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares of the company's stock, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,402,130 in the last quarter. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $116.78 on Wednesday. The stock has a 50-day simple moving average of $114.41 and a two-hundred day simple moving average of $110.06. The firm has a market capitalization of $144.90 billion, a P/E ratio of 23.26, a PEG ratio of 0.77 and a beta of 0.34. Gilead Sciences, Inc. has a fifty-two week low of $84.17 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same period last year, the business earned $2.01 earnings per share. Gilead Sciences's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.